Brigit Riley, Ph.D.

Dr. Riley is Adverum’s chief scientific officer, responsible for leading the company’s portfolio of drug discovery and development programs, including the AAV.7m8 platform. Dr. Riley has more than 15 years of experience in the biotechnology industry and in academia, identifying and advancing promising drug candidates into the clinic. She has expertise across a broad range of technologies and disease areas, including gene therapy, small molecules, antibodies, protein degradation, CNS and liver. Most recently Dr. Riley has been an advisor to several gene therapy companies. Previously, she was with Sangamo Therapeutics serving as vice president, discovery and translational research. She led the Hemophilia A program from initial gene cassette engineering to successful first in man clinical trial, resulting in a partnership with Pfizer. Additionally, she led Sangamo’s CNS portfolio and pipeline expansion, ultimately leading to a partnership with Biogen. Dr. Riley was also responsible for AAV engineering, liver rare disease and discovery efforts in engineering antibodies. She was a postdoctoral scholar at Stanford University, earned a Ph.D. in Biochemistry, Molecular Biology and Biophysics from University of Minnesota and a B.A. in Chemistry from Northwestern University.